tbuckley/cabot-search huggingface dataset:
Poor-Risk Acute Leukemia Patients with An EBMT Low-Risk Score and An 8/8 Matched Unrelated Donor Show Excellent Survival After Hematopoietic Stem Cell Transplantation.
Authors: Tom Lodewyck, Machteld Oudshoorn, Bronno van der Holt, Eefke Petersen, Eric Spierings, Peter A. Von Dem Borne, Anton Schattenberg, Wil Allebes, Ellen Meijer, Marlies Groenendijk-Sijnke, Lucia Duinhouwer, Roelof Willemze, Leo F. Verdonck, Bob Lowenberg, Jan J. Cornelissen
Journal: Blood (2009)
Progressive Epigenetic Programming during B Cell Maturation Is Reflected in a Continuum of Epigenetic Disease Phenotypes in Chronic Lymphocytic Leukemia
Authors: Christopher C. Oakes, Marc Seifert, Yassen Assenov, Lei Gu, Martina Przekopowitz, Amy S. Ruppert, Qi Wang, Charles Imbusch, Andrius Serva, Sandra Koser, David Brocks, Daniel B Lipka, Olga Bogatyrova, Benedikt Brors, Dieter Weichenhan, Laura Z. Rassenti, Thomas J. Kipps, Daniel Mertens, Marc Zapatka, Peter Lichter, Hartmut Döhner, Ralf Kueppers, Thorsten Zenz, Stephan Stilgenbauer, John C Byrd, Christoph Plass
Journal: Blood (2015)
Irreversible severe cardiotoxicities except for QTc interval prolongation associated with Osimertinib
Authors: Kei Kunimasa, Madoka Kimura, Makiko Oboshi, Takako Inoue, Motohiro Tamiya, Hanako Kuhara, Kazumi Nishino, Taku Yasui, Wataru Shioyama, Masashi Fujita, Fumio Imamura, Toru Kumagai
Journal: Annals of Oncology (2019)
Osteosarcoma Derived from Cultured Mesenchymal Stem Cells.
Authors: Jakub Tolar, Alma J. Nauta, Mark J. Osborn, Angela Panoskaltsis-Mortari, Ron T. McElmurry, Scott Bell, Lily Xia, Ning Zhou, Megan Riddle, Tania M. Schroeder, Jennifer J. Westendorf, R. Scott McIvor, Pancras C.W. Hogendoom, Karoly Szuhai, LeAnn Oseth, Betsy Hirsch, Stephen R. Yant, Mark A. Kay, Alexandra Peister, Darwin J. Prockop, Willem E. Fibbe, Bruce R. Blazar
Journal: Blood (2006)
Global impact of somatic structural variation on the DNA methylome of human cancers
Authors: Yiqun Zhang, Lixing Yang, Melanie Kucherlapati, Angela Hadjipanayis, Angeliki Pantazi, Christopher A. Bristow, Eunjung Alice Lee, Harshad S. Mahadeshwar, Jiabin Tang, Jianhua Zhang, Sahil Seth, Semin Lee, Xiaojia Ren, Xingzhi Song, Huandong Sun, Jonathan Seidman, Lovelace J. Luquette, Ruibin Xi, Lynda Chin, Alexei Protopopov, Peter J. Park, Raju Kucherlapati, Chad J. Creighton
Journal: Genome biology (2019)

Genomic rearrangements exert a heavy influence on the molecular landscape of cancer. New analytical approaches integrating somatic structural variants (SSVs) with altered gene features represent a framework by which we can assign global significance to a core set of genes, analogous to established methods that identify genes non-randomly targeted by somatic mutation or copy number alteration. While recent studies have defined broad patterns of association involving gene transcription and nearby SSV breakpoints, global alterations in DNA methylation in the context of SSVs remain largely unexplored.By data integration of whole genome sequencing, RNA sequencing, and DNA methylation arrays from more than 1400 human cancers, we identify hundreds of genes and associated CpG islands (CGIs) for which the nearby presence of a somatic structural variant (SSV) breakpoint is recurrently associated with altered expression or DNA methylation, respectively, independently of copy number alterations. CGIs with SSV-associated increased methylation are predominantly promoter-associated, while CGIs with SSV-associated decreased methylation are enriched for gene body CGIs. Rearrangement of genomic regions normally having higher or lower methylation is often involved in SSV-associated CGI methylation alterations. Across cancers, the overall structural variation burden is associated with a global decrease in methylation, increased expression in methyltransferase genes and DNA damage response genes, and decreased immune cell infiltration.Genomic rearrangement appears to have a major role in shaping the cancer DNA methylome, to be considered alongside commonly accepted mechanisms including histone modifications and disruption of DNA methyltransferases.
Clinical Characteristics and Quality of Life of Children with ITP Starting Second Line Treatments: Data from the ITP Consortium of North America ICON1 Study
Authors: Rachael F Grace, Robert J. Klaassen, Jennifer A Rothman, Kerry Hege, Ellis J Neufeld, Carolyn M. Bennett, Michele Lambert, Vicky R. Breakey, James B. Bussel, George R. Buchanan, Melissa J. Rose, Amy Geddis, Kristin Shimano, Kristina M. Haley, Adonis Lorenzana, Cindy Neunert, Alexis A. Thompson, Yves D. Pastore, Michael Jeng, Shelley E. Crary, Michelle Neier, Travis Brown, Peter Forbes, Jenny M. Despotovic
Journal: Blood (2016)
Dynamics of Cytogenetic Aberrations in Philadelphia Chromosome Positive and Negative Hematopoiesis during Dasatinib Therapy of Chronic Myeloid Leukemia Patients after Imatinib Failure.
Authors: Alice Fabarius, Claudia Schoch, Martin C. Mueller, Philipp Erben, Tanja Lahaye, Michelle Giehl, Oliver Frank, Wolfgang Seifarth, Rudiger Hehlmann, Andreas Hochhaus
Journal: Blood (2006)
Impact of Driver Mutations in Patients with Lower-Risk Myelodysplastic Syndromes Classified By the MD Anderson Lower-Risk Prognostic Scoring System
Authors: Guillermo Montalban-Bravo, Koichi Takahashi, Ana Alfonso Pierola, Feng Wang, Song Xingzhi, Elias J. Jabbour, Tapan M. Kadia, Farhad Ravandi, Jorge E. Cortes, Courtney D DiNardo, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Marina Konopleva, Graciela M. Nogueras-Gonzalez, Xuelin Huang, Carlos E. Bueso-Ramos, Andrew Futreal, Hagop M. Kantarjian, Guillermo Garcia-Manero
Journal: Blood (2016)
Possible Protective Role for Vδ1+ γδT Lymphocytes in Epstein-Barr Virus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
Authors: Masumi Fujishima, Makoto Hirokawa, Naohito Fujishima, Junsuke Yamashita, Hirobumi Saitoh, Yoshikazu Ichikawa, Takahiro Horiuchi, Yoshinari Kawabata, Ken-ichi Sawada
Journal: Blood (2006)
Gender Differences in Twitter Use and Influence Among Health Policy and Health Services Researchers
Authors: Jane M. Zhu, Arthur P. Pelullo, Sayed Hassan, Lillian Siderowf, Raina M. Merchant, Rachel M. Werner
Journal: JAMA Internal Medicine (2019)

number of clusters.Analyses were conducted in Stata SE 15 statistical package (StataCorp LLC).Statistical significance was defined as a 2-sided P < .05.Results | Of the 781 households (0.63%) that could not automatically reenroll in Covered California because of insurer exit, unadjusted and adjusted reenrollment rates were 21.4% and 21.5%, respectively (Table ).Both the unadjusted and adjusted reenrollment rates among the 122 463 households with the option to automatically reenroll were 51.2%.Losing the option to automatically reenroll was associated with a 30percentage point decrease in enrollment both with adjusting for household characteristics (95% CI, 9.4%-52.0%;P < .001)and without (95% CI, 14.2%-46.8%;P < .001).Discussion | Elimination of automatic reenrollment would likely be associated with decreases in the number of enrollees who remain insured through the marketplaces.As an opt-out policy 3 similar to that used in other health insurance markets such as Medicaid, 2 automatic reenrollment may be associated with increases in continuity of coverage in the marketplaces by reducing administrative barriers to reenrollment.Although we found losing an automatic reenrollment option was associated with decreases in reenrollment, this association requires further study.The group that lost the automatic reenrollment option was relatively small.Households with different demographics or different experiences with insurers may have behaved differently if they had lost the option to automatically reenroll.Losing automatic reenrollment because of policy changes rather than insurer exit also may be associated with households behaving differently.Given the magnitude of our findings, it is critical that future studies continue investigating the association between automatic reenrollment and continuity of coverage.
Updated Interim Results of the Safety and Efficacy of Different Lenalidomide Starting Dose Regimens in Patients with Relapsed or Refractory (rel/ref) Chronic Lymphocytic Leukemia (CLL) (CC-5013-CLL-009 Study)
Authors: Clemens Wendtner, Michael Hallek, Graeme Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Duerig, Stephanie A. Gregory, Matt Kalaycio, Stephan Stilgenbauer, Andreas Buehler, Thomas J. Kipps, Brendan Purse, Jennie Zhang, Jay Mei, Asher Chanan-Khan
Journal: Blood (2012)
Minimal Residual Disease (MRD)-Oriented Therapy of Adult Acute Lymphoblastic Leukemia (ALL): Final Results of Northern Italy Leukemia Group Study 09/00.
Authors: Renato Bassan, Orietta Spinelli, Elena Oldani, Tamara Intermesoli, Manuela Tosi, Barbara Peruta, Vittoria Guerini, Giuseppe Rossi, Enrico Pogliani, Eros Di Bona, Pietro Fabris, Agostino Cortelezzi, Teodoro Chisesi, Emanuele Angelucci, Franco Leoni, Fabio Ciceri, Daniele Mattei, Tiziano Barbui, Alessandro Rambaldi
Journal: Blood (2007)
The Human Ankyrin Insulator Supports Production of Therapeutic Levels of Adult Hemoglobin Following β-Globin Gene Transfer in Hematopoietic Cells Derived From Thalassemic and Sickle Cell Patients
Authors: Laura Breda, Carla Casu, Nicoletta Bianchi, Luca Cartegni, Karina Yazdanbakhsh, Deepa Manwani, Narla Mohandas, Petar Jelinic, Gregory David, Lawrence B. Gardner, Dorothy A Kleinert, Eugenia Prus, Eitan Fibach, Patricia Giardina, Roberto Gambari, Stefano Rivella
Journal: Blood (2011)
Impact of Reduced Dose Intensity for Elderly Patients with Diffuse Large B-CELL Lymphoma Receiving R-CHOP Every 14 or 21 Days: An Analysis of the LNH03–6B GELA Study.
Authors: Richard Delarue, Herve Tilly, Gilles Salles, Catherine Thieblemont, Nicolas Mounier, Thierry Jo Molina, Serge Bologna, Corinne Haioun, Andre Bosly
Journal: Blood (2012)
Higher Doses of Antithymocyte Globulin (ATG) Increase the Risk of Relapse in Acute Myeloid Leukemia (AML) Patients Undergoing Matched Related Donor Allogeneic Transplantation in First Complete Remission (CR1): An Analysis from the Acute Leukemia Working Party of EBMT
Authors: Raynier Devillier, Myriam Labopin, Patrice Chevallier, Bruno Lioure, Gerard Socie, Anne Huynh, Jean-Henri Bourhis, Jean-Yves Cahn, Mauricette Michallet, Laure Vincent, Frederic Baron, Didier Blaise, Arnon Nagler, Mohamad Mohty
Journal: Blood (2014)
Whole Brain Radiotherapy and Ara-C In Consolidation Post High-Dose Methotrexate Is Important In Establishing Durable Disease Control In the Treatment of Primary CNS Lymphoma: A Single Centre Observational Study
Authors: Hang Quach, Melody Abikhair, Michael MacManus, Ron Freilich, Beena Kumar, Ian Simpson, Stephen Opat
Journal: Blood (2010)
Novel Multistage Nanoparticle Drug Delivery to Ablate Leukemia Stem Cells in Their Niche.
Authors: Hongliang Zong, Siddhartha Sen, Guodong Zhang, David G Gorenstein, Xuewu Liu, Mauro Ferrari, Gail J. Roboz, Haifa Shen, Monica L. Guzman
Journal: Blood (2012)
SAR650984 (SAR) Directly Promotes Homotypic Adhesion-Related Multiple Myeloma (MM) Cell Death and SAR-Induced Anti-MM Activities Are Enhanced By Pomalidomide, More Potently Than Lenalidomide
Authors: Hua Jiang, Gang An, Chirag Acharya, Mike Y Zhong, Ti Cai, Zhili Song, Guang Yang, Francisco Adrian, Nikhil C. Munshi, Yu-Tzu Tai, Kenneth C. Anderson
Journal: Blood (2014)
The Proportion of Clonal Plasma Cells In the Bone Marrow Analyzed by FISH Rather Than Single Chromosomal Abnormalities Predict Progression From Smoldering to Symptomatic Multiple Myeloma
Authors: Kai Neben, Anna Jauch, Dirk Hose, Christiane Heiss, Thomas Hielscher, Uta Bertsch, Anja Seckinger, Jens Hillengass, Marc S. Raab, Anthony D. Ho, Hartmut Goldschmidt
Journal: Blood (2010)
Factors affecting treatment strategy, completion of planned treatment and survival in older patients with glioblastoma
Authors: Aimee Goel, Lillie Shahabi, Ganesalingam Narenthiran, Kevin O’Neill, David Peterson, Dipankar Nandi, Matthew Williams, W Saleem, A Falconer, Sophie Camp
Journal: Neuro-Oncology (2019)

Abstract Introduction For older patients with glioblastoma (GBM), age, extent of resection, and performance status are prognostic factors. However, an international survey conducted by our Unit found that &gt;40% of neurosurgeons use age alone to discount surgery in older (65+) patients. The aim of this study was to review management in our Unit for 65+ GBM patients, to inform future approaches. Methods Patients 65+ with a new GBM diagnosis in our Unit, between 2014 and 2017, were identified. Demographic data, performance status (PS), comorbidity and frailty indices, together with details of surgical/oncological management and outcome were collected. Results 78 patients were identified. 78% aged 65–74 underwent maximal safe resection, compared with 45% aged 75–84, and 10% aged 85+. Resection was undertaken in 68% PS1, 73% PS2 and 23% PS3 patients. No PS3 patient completed intended radiotherapy, compared with 79% PS1 and 74% PS2 patients. There was a significant difference in frailty scores of patients who completed scheduled oncological therapy compared with those who did not (median score 2 vs 4.5, p=0.0338). Median survival was 10 months for patients 65–74, 4 months for aged 75 -84, and 40 days for 85+ (p&lt;0.0167). Median survival was significantly lower for PS3 patients (44 days) compared with PS1 or 2 (9.5 months and 7 months respectively; p&lt;0.0167). Conclusion There is considerable variability in performance status and frailty of 65+ GBM patients. PS3 patients at diagnosis are very unlikely to complete oncological treatment. These factors, rather than age alone, should be used to guide management decisions.
Phase 2 Study of E7777, a Diphtheria Toxin Fragment-Interleukin-2 Fusion Protein, in Japanese Patients with Relapsed or Refractory Peripheral and Cutaneous T-Cell Lymphoma
Authors: Dai Maruyama, Kiyoshi Ando, Kazuhito Yamamoto, Eiji Kiyohara, Yasuhito Terui, Noriko Fukuhara, Tomomitsu Miyagaki, Hidetsugu Kawai, Yoshiki Tokura, Mamiko Sakata-Yanagimoto, Tadahiko Igarashi, Junya Kuroda, Jiro Fujita, Toshiki Uchida, Takayuki Ishikawa, Kentaro Yonekura, Koji Kato, Tadashi Nakanishi, Kenya Nakai, Risa Matsunaga, Kensei Tobinai
Journal: Blood (2019)
Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Refractory Severe Aplastic Anemia (SAA)
Authors: Amy E. DeZern, Donna Dorr, Leo Luznik, Javier Bolanos-Meade, Christopher Gamper, Heather J. Symons, Kenneth R. Cooke, Richard J. Jones, Robert A. Brodsky
Journal: Blood (2015)
Integrated Genetic and Epigenetic Analysis of Childhood Acute Lymphoblastic Leukemia Reveals a Synergistic Role for Structural and Epigenetic Lesions In Determining Disease Phenotype
Authors: Maria E. Figueroa, Shann-Ching Chen, Anna K. Andersson, Wei Liu, Cheng Cheng, Letha A Phillips, Yushan Li, James R. Downing, Ari M. Melnick, Charles Mullighan
Journal: Blood (2010)
Results of An International Study of Quantitative BCR/ABL Assays Using Defined RNA Samples
Authors: Dorie A. Sher, Jeffrey E. Miller, Qi Wei, Jerald P. Radich, Chris L.P. Wong, Iris Schrijver, B. Kelly McNeil, Elisa Romeo, Eric Winstall, Lurdes Zamora, Claire Abbal, Katrien Pieters, Dolors Colomer, Brigitte Maes, Phillippe Van Lint, Pierre JJC DeSchouwer, Marleen Bakkus, Celine Callens, Barbara Denys, Nancy Boeckx, Peter Vandenberghe, Freya Vaeyens, Hongxin Fan, Sherry Taylor, George Georgiou, Thomas J. Monroe, Kimberly Hocker, Teresa Webb-Martin, Heather Todd, Adriana Muniz-Fernandez, Hanfang Zhang, Petr Starostik, C. Renee Webb, Li Cai, Christopher Watt, Linda Fletcher, Suzan Lambin, Oscar Fuster, Ying Huang, Jay H. Shaw
Journal: Blood (2010)
CEACAM-1 Is Involved in Graft-Versus-Host-Disease in Murine Allogeneic Bone Marrow Transplantation Models.
Authors: Sydney X. Lu, Lucy Willis, Marsinay Smith, David Suh, Christopher King, Johanne Bautista, Melanie Chow, Javier Cabrera-Perez, Vanessa Hubbard, Jimmy Rotolo, Chen Liu, George Murphy, Onder Alpdogan, Richard Blumberg, Kathryn Holmes, Claire Turbide, Nicole Beauchemin, Marcel R.M. van den Brink
Journal: Blood (2007)
MiR-155 Regulates Acute GvHD By Reducing NLRP3 Inflammasome Activity Via Targeting SOCS1 In Antigen-Presenting Cells
Authors: Sophia Chen, Joseena Iype, Sebastian Grundmann, Marco Idzko, Annette Schmitt-Gräff, Heide Dierbach, Yvonne Beck, Jürgen Finke, Justus Duyster, Robert Zeiser
Journal: Blood (2013)
Updated Analysis of Allogeneic HSCT after RIC for Hematological Malignancies from the Société Française de Greffe de Moelle Osseuse et de Thérapie Cellulaire (SFGM-TC) Registry.
Authors: Mauricette Michallet, Quoc-Hung Le, Mohamad Mohty, Franck E. Nicolini, Jean-Michel Boiron, Hélène Espérou, Michel Attal, Noel Milpied, Bernard Lioure, Pierre Bordigoni, Ibrahim Yackoub-Agha, Jean-Henri Bourhis, Bernard Rio, Eric Deconninck, Marc Renaud, Mohamad Sobh, Nicole Raus, Didier Blaise
Journal: Blood (2007)
Bilateral hypoglossal nerve stimulation for treatment of adult obstructive sleep apnoea
Authors: Peter R. Eastwood, Maree Barnes, Stuart G. MacKay, John R. Wheatley, David R. Hillman, Xuân-Lan Nguyên, Richard Lewis, Matthew C. Campbell, Boris Pételle, Jennifer H. Walsh, Andrew C. Jones, Carsten E. Palme, Alain Bizon, Nicole Meslier, Chloé Bertolus, Kathleen J. Maddison, Laurent Laccourreye, Guillaume Raux, Katleen Denoncin, Valérie Attali, Frédéric Gagnadoux, Sandrine H. Launois
Journal: European Respiratory Journal (2019)

Background and aim Hypoglossal nerve stimulation (HNS) decreases obstructive sleep apnoea (OSA) severity via genioglossus muscle activation and decreased upper airway collapsibility. This study assessed the safety and effectiveness at 6 months post-implantation of a novel device delivering bilateral HNS via a small implanted electrode activated by a unit worn externally, to treat OSA: the Genio™ system. Methods This prospective, open-label, non-randomised, single-arm treatment study was conducted at eight centres in three countries (Australia, France and the UK). Primary outcomes were incidence of device-related serious adverse events and change in the apnoea–hypopnoea index (AHI). The secondary outcome was the change in the 4% oxygen desaturation index (ODI). Additional outcomes included measures of sleepiness, quality of life, snoring and device use. This trial was registered with ClinicalTrials.gov, number NCT03048604 . Results 22 out of 27 implanted participants (63% male, aged 55.9±12.0 years, body mass index (BMI) 27.4±3.0 kg·m −2 ) completed the protocol. At 6 months BMI was unchanged (p=0.85); AHI decreased from 23.7±12.2 to 12.9±10.1 events·h −1 , a mean change of 10.8 events·h −1 (p&lt;0.001); and ODI decreased from 19.1±11.2 to 9.8±6.9 events·h −1 , a mean change of 9.3 events·h −1 (p&lt;0.001). Daytime sleepiness (Epworth Sleepiness Scale; p=0.01) and sleep-related quality of life (Functional Outcomes of Sleep Questionnaire-10; p=0.02) both improved significantly. The number of bed partners reporting loud, very intense snoring, or leaving the bedroom due to participant snoring decreased from 96% to 35%. 91% of participants reported device use &gt;5 days per week, and 77% reported use for &gt;5 h per night. No device-related serious adverse events occurred during the 6-month post-implantation period. Conclusions Bilateral HNS using the Genio™ system reduces OSA severity and improves quality of life without device-related complications. The results are comparable with previously published HNS systems despite minimal implanted components and a simple stimulation algorithm.
Dual Mode of Involvement of Transcriptional Mediator Subunit MED1 In GATA1-Mediated Erythroid Differentiation of K562 Erythroleukemia Cells
Authors: Shumpei Mizuta, Tomoya Minami, Chihiro Kaminaga, Kasumi Oda, Keiji Matsui, Akiko Sumitomo, Ruri Ishino, Mitsuhiro Ito
Journal: Blood (2010)
Recombinant β2-Glycoprotein I (β2GPI) Produced Using a Novel Lentiviral Approach Functions at Least As Well As Plasma-Derived β2GPI in Detection of Anti-β2GPI Antibodies
Authors: Mohamed Samour, Shruti Chaturvedi, Sergei Merkulov, Caner Saygin, Heesun J Rogers, Suman Kundu, Keith R. McCrae
Journal: Blood (2016)
Molecular Monitoring and Tailored Strategy with Pre-Emptive Rituximab Treatment for Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-up of 8.5 Years
Authors: Arne Kolstad, Lone B Pedersen, Christian Winther Eskelund, Simon Husby, Kirsten Grønbæk, Mats Jerkeman, Anna Laurell, Riikka Räty, Erkki Elonen, Niels S. Andersen, Peter de Nully Brown, Christian H Geisler
Journal: Blood (2016)
Genetic and Epigenetic Studies Reveal That Murine Oct-4+ Very Small Embryonic/Epiblast-Like Stem Cells (VSELs) Present in Adult Tissues Share Several Similarities/Markers with Epiblast-Derived Migratory Primordial Germ Cells (PGCs).
Authors: Dong-Myung Shin, Ewa Zuba-Surma, Rui Liu, Mariusz Z Ratajczak, Magdalena Kucia
Journal: Blood (2009)
Kinase Activity of RTKs Is Dispensable for Factor Independent Growth and Transformation of a Myeloid Cell Line 32D in the Presence of Cbl Mutants.
Authors: Srinivasa Rao Bandi, Marion Rensinghoff, Rebekka Grundler, Lara Tickenbrock, Justus Duyster, Wolfgang E Berdel, Christian Brandts, Hubert Serve, Carsten Müller-Tidow
Journal: Blood (2009)
Prognostic Score Based on Clinical and Biochemical Surrogates of Disease Status in DLBCL Trated with Chemo-Immunotherapy
Authors: Luigi Marcheselli, Alessia Bari, Samantha Pozzi, Raffaella Marcheselli, M. Christina Cox, Luca Baldini, Stefano Luminari, Stefano Sacchi
Journal: Blood (2014)
An Angiogenic Risk Score Improves the Prognostic Information of the International Staging System in Patients with Symptomatic Multiple Myeloma.
Authors: Christian Jakob, Theresa Wernecke, Jan Sterz, Andrea Goerke, Ulrike Heider, Martin Kaiser, Maren Mieth, Susanne Ziefle, Orhan Sezer
Journal: Blood (2009)
Alterations of BRCA1 and PALB2 Define a Novel Class of Complex-Karyotype AML with a Very Bad Prognosis
Authors: Antonella Padella, Giorgia Simonetti, Marco Manfrini, Maria Chiara Fontana, Giovanni Marconi, Anna Ferrari, Italo Faria do Valle, Marianna Garonzi, Cristina Papayannidis, Eugenia Franchini, Elisa Zuffa, Viviana Guadagnuolo, Samantha Bruno, Elena Tenti, Carmen Baldazzi, Emanuela Ottaviani, Nicoletta Testoni, Daniel Remondini, Massimo Delledonne, Giovanni Martinelli
Journal: Blood (2016)
Interactions Between BAFF and BAFF Receptors Are Involved in Macrophage-Induced Bortezomib Resistance in Myeloma
Authors: Jing Chen, Donghua He, Xing Guo, Qingxiao Chen, Xuanru Lin, Jingsong He, Xi Huang, Haimeng Yan, Yi Li, Li Yang, Yang Yang, Enfan Zhang, He Huang, Zhen Cai
Journal: Blood (2016)
Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma
Authors: Daruka Mahadevan, Laurence Cooke, Xiaobing Liu, Daniel Oscar Persky, Catherine M. Spier, Thomas P. Miller, Wenqing Qi
Journal: Blood (2010)
Acadesine-Induced Citotoxicy In Chronic Lymphocytic Leukemia Is Independent of Immunoglobulin Mutational Status and Zap70 Expression
Authors: Silvia Pairet, Ana Ferrer, Eugenia Abella, MariCarmen Vela, Raquel Longarón, Clara Campàs, Mercè de Frías, Aina Pons, Blanca Espinet, Sergi Serrano, Carlos Besses, Beatriz Bellosillo
Journal: Blood (2010)
Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugates
Authors: Noriko Satake, Connie Duong, Michael Oestergaard, Sakiko Yoshida, Cathy Chen, Jan A. Nolta, Shuling Guo, Punit Seth, Nitin Nitin, Joseph Tuscano
Journal: Blood (2014)